肾性贫血处理:铁剂治疗

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户：ADAM129XU

【摘要】

：

铁是合成血红蛋白的基本原料.流行病学及临床的研究证实在慢性肾脏病(CKD)贫血患者中常常存在一定程度的铁缺乏[1,2],铁缺乏也是导致红细胞刺激剂(ESA)治疗反应差的主要原因,予以充足的铁补充 ,不仅可以明显改善贫血,还可以减少ESA的使用剂量,甚至在未使用ESA的情况下也能改善贫血[3,4].因此对于CKD贫血患者需常规进行铁状态的评价,搜寻导致铁缺乏的原因.并根据患者的铁状态予以相应的铁剂补

【出处】

：

2013年中国肾性贫血治疗专家共识研讨会

【发表日期】

：

2012年12期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatme

Background.Iron deficiency is a common cause of anaemia and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent chronic kidney disease (ND-CKD) patients.Current in

会议

anaemiaCKDferritinintravenous irontransferrin saturation

Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and

Few data exist to guide treatment of anemic hemodialysis patients with high ferritin and low transferrin saturation (TSAT).The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) trial

会议

A randomized, controlled trial comparing Ⅳ iron sucrose to oral iron in anemic patients with nondial

A randomized, controlled trial comparing Ⅳ iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.Background.Although iron deficiency frequently complicates anemia in patients wit

会议

CKDanemiaironiron deficiencyiron sucrose

Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review a

Background: Iron supplementation is essential for the treatment of patients with anemia of chronic kidney disease (CKD).It is not clear which is the best method of iron administration.Study Design: Sy

会议

Anemiaironchronic kidney diseasehemodialysishemoglobinmeta-analysis

A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplement

Background.Concomitant iron supplementation is required in the great majority of erythropoietin (Epo)-treated patients with end-stage renal failure.Intravenous (i.v.) iron supplementation has been dem

会议

erythropoietinferritinhaemoglobinsiron economicsperitoneal dialysisprospect

Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin

Background.Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients.However, the optimal

会议

anaemiaepoetinshaemodialysisiron sucroseoutcome

Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients

Iron deficiency limits the efficacy of recombinant human erythropoietin (rhEPO) therapy in end-stage renal disease (ESRD)patients.Functional iron deficiency occurs with serum ferritin >500 ng/ml and/o

会议

Ferumoxytol for Treating Iron Deficiency Anemia in CKD

Iron deficiency is an important cause of anemia in patients with chronic kidney disease (CKD), but intravenous iron is infrequently used among patients who are not on dialysis.Ferumoxytol is a novel i

会议

Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammat

Background: Serum ferritin, frequently used as a marker of iron status in individuals with chronic kidney disease, is also an inflammatory marker.The concurrent combination of high serum ferritin and

会议

Serum Ferritin Level Remains a Reliable Marker of Bone Marrow Iron Stores Evaluated by Histomorphome

Background and objectives: As well as being a marker of body iron stores, serum ferritin (sFerritin) has also been shown to be a marker of inflammation in hemodialysis (HD) patients.The aim of this st

会议

肾性贫血处理:铁剂治疗

与本文相关的学术论文